Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human macrophages from Crohns disease patients or healthy control individuals, either unstimulated or stimulated with heat killed E. coli;
Comparison of gene expression in macrophages from Crohn's disease patients or healthy control individuals, either unstimulated or stimulated with heat killed E. coli
ORGANISM(S): Homo sapiens 
2009-08-03 | E-TABM-733 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human macrophages from ulcerative colitis patients or healthy control individuals, either unstimulated or stimulated with heat killed E. coli
Comparison of gene expression in macrophages from ulcerative colitis patients or healthy control individuals, either unstimulated or stimulated with heat killed E. coli
ORGANISM(S): Homo sapiens 
2009-08-03 | E-TABM-734 | biostudies-arrayexpress
UnknownAtaluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Not available
S-EPMC4154311 | biostudies-literature
UnknownCutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Not available
S-EPMC10308295 | biostudies-literature
UnknownSTK19 facilitates the clearance of lesion-stalled RNAPII during transcription-coupled DNA repair.
Not available
S-EPMC12287594 | biostudies-literature
UnknownLoci for insulin processing and secretion provide insight into type 2 diabetes risk.
Not available
S-EPMC9943750 | biostudies-literature
UnknownCommon variants near MC4R are associated with fat mass, weight and risk of obesity.
Not available
S-EPMC2669167 | biostudies-literature
UnknownGenome-wide association study identifies eight loci associated with blood pressure.
Not available
S-EPMC2891673 | biostudies-literature
UnknownGenetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes.
Not available
S-EPMC2798726 | biostudies-literature
UnknownFinal, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Not available
S-EPMC12080919 | biostudies-literature
Sort   by:  
 Page size